SCHEMBL4424399

SCHEMBL4424399

CCN1C(=O)CN=C(c2cccc(C(N)=O)c2)c2c1cc(OC)c(-c1ccccc1)c2OC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 1/20 0.60
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
FYN P06241 1/20 0.39
PTGDR2 Q9Y5Y4 6/20 0.39
KDM4E B2RXH2 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ALDH1A1 P00352 1/20 0.37
PDE4D Q08499 1/20 0.37
PGK1 P00558 1/20 0.36
ATR Q13535 1/20 0.36
ERN1 O75460 1/20 0.36
USP2 O75604 1/20 0.36
POLB P06746 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
HTT P42858 1/20 0.36
PIK3CG P48736 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4602359 0.96 PDE2A (0.58) PDE2ATP53MAPTFYNPTGDR2
SCHEMBL4412620 0.93 PDE2A (0.60) PDE2ATP53MAPTFYNPTGDR2
SCHEMBL4411561 0.91 PDE2A (0.58) PDE2ATP53MAPTFYNPTGDR2
SCHEMBL4414065 0.90 PDE2A (0.56) PDE2ATP53MAPTFYNPTGDR2
SCHEMBL4412658 0.89 PDE2A (0.72) PDE2AFYNPDE4DATRERN1
SCHEMBL4414019 0.88 PDE2A (0.57) PDE2ATP53MAPTPTGDR2KDM4E
SCHEMBL4423211 0.87 PDE2A (0.54) PDE2ATP53MAPTFYNPTGDR2
SCHEMBL4423000 0.85 PTGDR2 (0.55) PDE2ATP53MAPTPTGDR2HTT
SCHEMBL4708304 0.85 PDE2A (0.66) PDE2ATP53MAPTFYNPTGDR2
SCHEMBL4413377 0.83 GABRA1 (0.45) PDE2ATP53MAPTPTGDR2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215752-A1 Compounds, preparation and therapeutic use thereof BAY CITY CAPITAL LLC 2009-08-27 US claimed
EP-1910315-A2 BENZODIAZEPINE DERIVATIVES, THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF NEURO3D (FR) 2008-04-16 EP claimed
WO-2007026254-A2 BENZODIAZEPINE DERIVATIVES , THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF NEURO3D (FR) 2007-03-08 WO claimed
EP-1749824-A1 Benzodiazepine derivatives, their preparation and the therapeutic use thereof NEURO3D (FR) 2007-02-07 EP claimed
US-20090215752-A1 Compounds, preparation and therapeutic use thereof BAY CITY CAPITAL LLC 2009-08-27 US disclosed
EP-1749824-A1 Benzodiazepine derivatives, their preparation and the therapeutic use thereof NEURO3D (FR) 2007-02-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215752-A1 Compounds, preparation and therapeutic use thereof PDE12, PDE4B, PDE2A PDE2A 3/4885TP53 4884/4885MAPT 2304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.